Two drugs have been approved in recent years in
Europe for hospital-acquired and/or ventilator-associated bacterial pneumonia
(HABP/VABP), but not in the U.S. At least 11 compounds are in clinical
development to treat bacterial pneumonia. The three Phase I programs have the
potential to go directly to Phase III based on data in other indications. Trius
Pharmaceuticals Inc. (NASDAQ:TSRX) has tedizolid phosphate in Phase III for
acute bacterial skin and skin structure infections (ABSSI). Cubist
Pharmaceuticals Inc. (NASDAQ:CBST